| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
*
Medicine and
Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
We and others found that long-term but not short-term administration of CTLA4Ig to New Zealand Black/New Zealand White (NZB/NZW) F1 mice prevented the onset of SLE, but that disease manifestations appeared 4–8 wk after stopping treatment (7, 8). In contrast, a 2-wk course of anti-CD40L given early in life caused a 2- to 3-mo delay in the onset of disease. This was apparently due to inactivation of autoimmune B cells, with T cell function remaining intact (9). Synergy between these two reagents has been observed in several transplantation models and in induced autoimmunity models where administration of drug can be timed according to the time of Ag exposure (10). In the spontaneous autoimmune disease SLE, Daikh et al. (11) reported that a 2-wk course of combined therapy using CTLA4Ig and anti-CD40L given to prenephritic 5-mo-old mice that already display some evidence of an activated autoimmune phenotype delayed disease onset for up to 6 mo. The mechanism for this effect has not been characterized and the understanding of this issue is crucial to the development of therapeutic regimens for humans with already established autoimmune disease.
The goal of this study was to understand the immunologic effects of combined CTLA4Ig and anti-CD40L therapy on the development, selection, and activation of pathogenic anti-dsDNA Ab-producing B cells and on the activation of T cells in the NZB/NZW F1 murine model of SLE. We found that a 2-wk course of treatment of prenephritic mice with combination CTLA4Ig/anti-CD40L resulted in delayed onset of renal dysfunction, a marked decrease in the frequency of B cells producing IgG anti-DNA Abs, a partial suppression of class switching, and inhibition of T cell activation and switching to a memory phenotype. In contrast, treatment did not appear to affect the abnormal activation or selection of naive autoreactive B cells. Using an autoreactive V region gene as a marker, we were able to show a long-term effect on somatic mutation and on selection specifically of autoreactive B cells without any adverse effect on the response to foreign Ag, indicating that this therapy did not mediate its effects via global immunosuppression. After onset of proteinuria, a repeat course of treatment was able to induce remission in previously treated but not in previously untreated mice and several mice became long-term survivors. These results shed new light on the mechanisms by which short-term costimulatory blockade inhibits autoreactive B cell maturation and prevents SLE onset.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
NZB/NZW F1 females were purchased from The Jackson Laboratory (Bar Harbor, ME) and maintained in a conventional animal housing facility throughout the experiment. Fully murine CTLA4Ig was obtained from the serum of SCID mice injected with a CTLA4Ig-expressing adenovirus (8). Mice were treated at the age of 20–22 wk with a combination of 100 µg of CTLA4Ig and 250 µg of anti-CD40L (MR1, a kind gift of Dr. S. Kalled, Biogen, Cambridge, MA), each given i.p. six times over a 2-wk period (24 mice). Control mice received either CTLA4Ig alone (12 mice), anti-CD40L alone (13 mice), or combination mouse IgG2a and hamster IgG (21 mice). Before treatment, mice were tested for anti-dsDNA Abs and were randomized into treatment groups depending on the titer of Abs. Mice were bled every 2–4 wk. Urine was tested for proteinuria by dipstick (Multistick; Fisher, Pittsburgh, PA) every 2 wk. Mice that received combination therapy or that were previously untreated with any therapy or control Ab (14 mice) received a 2-wk course of combination therapy as above when they developed fixed proteinuria of 300 mg/dl. Survival splenectomies were performed at intervals following treatment. One group of 14 combination-treated mice was followed for 2 years. The remaining mice were followed until 18 mo (78 wk) of age. Mice injected with a single dose of adenovirus-CTLA4Ig have been described previously (8).
Anti-DNA Abs
ELISA plates (Falcon) were coated with 100 µl of 100 µg/ml salmon sperm DNA made double stranded by passage through a 45-µm filter (USA Scientific, Ocala, FL). After drying, the plates were blocked and then incubated sequentially for 1 h at 37°C with serial dilutions of serum followed by peroxidase-conjugated F(ab')2 goat anti-mouse Ig (1/8000) or anti-IgG2a (1/5000) in PBS/1% BSA (Accurate Antibodies, Westbury, NY) and then ABTS substrate (Kirkegaard & Perry, Gaithersburg, MD).
ELISPOT assay
Spleens were harvested 16–20 wk after the first treatment and 4–8 wk after the second treatment. Four to five mice were examined in each group. Threefold serial dilutions of spleen cells were plated in duplicates overnight on DNA-coated plates starting at 1 x 106 cells per well. After washing, the plates were incubated with biotin-conjugated anti-IgM or anti-IgG (Southern Biotechnology Associates, Birmingham, AL) 1/1000 in PBS/1% BSA for 2 h, followed by streptavidin alkaline phosphatase (Southern Biotechnology Associates) 1/1000 in PBS/1% BSA for 45 min. Plates were then developed with 1 mg/ml 5-bromo-4-chloro-3-indolyl phosphate (Sigma-Aldrich, St. Louis, MO) in AMP buffer (0.75 mM MgCl/0.01% Triton-X/9.58% 2-amino-methyl-1-propanol, pH 10.25). Spots were counted using a dissecting microscope. Total numbers of Ig-secreting cells were measured the same way using anti-mouse Igs (Cappel, Westchester, PA) to coat the plates.
Generation of hybridomas
Hybridomas were generated from spleen cells by standard techniques using NSO cells as fusion partner. In some cases, spleen cells were also stimulated with 20 µg/ml LPS (Sigma-Aldrich) for 48 h before fusion. Hybridomas were screened for anti-dsDNA activity by ELISA as above. Positive hybridomas were then isotyped using specific peroxidase-conjugated secondary Abs for IgM and IgG (Cappel).
Analysis of class switching
Evidence of active class switching was sought by
semiquantitative RT-PCR analysis of I-C transcripts from spleens of
five treated and five age-matched control mice. cDNA was generated
using random primers, normalized for cDNA content using actin primers,
and subjected to PCR using primers for the I
2b and C2b and for
the I1 and C1 exons, as previously described
(8).
Analysis of the VHBW-16 gene
To understand the molecular basis for the treatment-induced decrease in frequency of B cells producing anti-dsDNA Abs of the IgG isotype, we performed a detailed analysis of the VHBW-16 gene as we have previously described (8). IgG cDNA libraries were constructed by RT-PCR from the spleens of 10 combination-treated mice and eight age-matched controls. Two hundred to 400 colonies from each library were hybridized at 54°C with two VHBW-16-specific oligomers (complementarity-determining region (CDR)1, 5'-CTGCTGCAAGGCTTCTGGTT-3'; CDR2, 5'-GGAATTAATCCTTACTATGGT-3'). The quality of each library was confirmed by stripping and rehybridizing each filter with the IgM or IgG constant region oligomers. Positive colonies were picked and inserts from purified plasmids were sequenced in the Albert Einstein College of Medicine sequencing facility.
Sequences were compared with the germline
VHBW-16 sequence using a basic local alignment
search tool search (http://www.ncbi.nlm.nih.gov/blast/). Mutations were
analyzed in the V region only and the last four nucleotides of the V
region were excluded from the mutation analysis, as there were many
differences in these nucleotides due to junctional diversity.
Replacement to silent mutation ratios were calculated and the frequency
of mutations at the RGYW hot spot on both strands was determined
(12). Mutations shared by more than one clonally related
sequence were analyzed only once. Comparisons of percentage of hot spot
mutations in treated vs untreated mice were performed using the
2 test. Finally, the number of transitions and
transversions was determined and compared with the expected number of
randomly generated mutations based on the frequency of each nucleotide
in the VHBW-16 sequence.
Flow cytometry
Spleen cells were analyzed for B and T cell markers using Abs to CD4 (Caltag Laboratories, Burlingame, CA), CD8 (Caltag Laboratories), and CD19 (BD PharMingen, San Diego, CA). Presence of activated CD4 cells was determined by double staining with FITC-anti-CD4 and PE-anti-CD69 (BD PharMingen). Presence of naive and activated/memory CD4 cells was determined by triple staining with FITC-anti-CD4, CyChrome-anti-CD44 (BD PharMingen), and PE-anti-CD62L (BD PharMingen).
Oxazolone immunization
To determine whether therapy had long-term effects on the immune response to foreign Ag, groups of five mice were immunized with 750 µg of the hapten oxazolone (Sigma-Aldrich) by skin paint in olive oil/acetone on the shaved abdomen 8 wk after initiation of treatment. Mice were bled at weekly intervals thereafter. Four to 6 wk later mice were boosted with 30 µg of oxazolone by skin paint and spleens were harvested for analysis 3 days later.
Anti-oxazolone Abs
Anti-oxazolone Abs were measured by ELISA as previously described (13). In brief, plates were coated overnight with 100 µg/ml oxazolone-coupled BSA (Ox-BSA), blocked, and then incubated sequentially with serum at either 1/500 or 1/2000 dilution in PBS/1% BSA at 37°C for 1 h, anti-mouse IgG at 1/5000 dilution in PBS/1% BSA at 37°C for 1 h, and ABTS substrate.
Anti-oxazolone ELISPOTs
Plates were coated with Ox-BSA as above and ELISPOTs were performed exactly as described for dsDNA as above.
Analysis of the VH-Ox15 gene
To determine whether the immune response to oxazolone underwent
affinity maturation, cDNA libraries were made of the
VH-Ox15 gene from spleens of four
combination-treated and three control mice. The
VH-Ox15 gene dominates the anti-oxazolone
response in BALB/c mice (14), and we had previously
determined that 
30% of anti-oxazolone hybridomas from immunized
but otherwise unmanipulated NZB/NZW F1 mice use
this H chain gene (M. Mihara and A. Davidson, unpublished data). The
sequence of the NZB/NZW F1
VH-Ox15 gene differs from the BALB/c sequence by
two nucleotides, with a single amino acid difference (Gly-Val) at
position 10 (M. Mihara and A. Davidson, unpublished observation). cDNA
libraries were generated using a VH-Ox15 leader
primer (5'-GCCCCCATCAGAGCATGGC) and an IgG constant region primer
(8). Colonies were screened with a leader primer
downstream of the primer used for PCR (5'-TGCCTGGTTGCATTTCCAA) and
with a framework 3 primer (5'-AGCAAAGACAACTCCAAGAGC). Initial
sequence analysis of 30 colonies revealed that only those colonies that
hybridized with both primers contained the correct gene so that
subsequently only double-positive colonies were picked for sequencing.
Positive colonies were then analyzed for mutations as above. For
comparison, analysis of the VHBW-16 gene was
performed on the same spleens.
Statistical analysis
Proteinuria, survival, and anti-DNA Ab data shown in
Figs. 1–3
were analyzed using Kaplan Meier curves and log rank test.
Comparisons shown in Figs. 3, 5, 9, and 10 were performed using
Wilcoxon rank sum test. Comparisons shown in Figs. 4 and 7 and Table I were performed using
2 analysis or Fisher’s exact test. Only
significant p values are shown.
|
|
|
|
|
|
|
|
|
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Combination therapy with 2 wk of CTLA4Ig and anti-CD40L, but
not single therapy with either agent alone, delayed the onset of
proteinuria (Fig. 1
). Seventeen percent
of combination-treated mice had not developed proteinuria by age 74 wk
compared with 0% of mouse IgG2a/hamster IgG-treated controls
(p < 0.0001). Retreatment with a second course
of therapy at the time of onset of proteinuria resulted in complete
remission (defined as reversion of proteinuria to 30 mg/dl lasting at
least 6 wk) in 11 of 21 combination-treated mice compared with only two
of 14 previously untreated controls (p <
0.04). Durable remissions of 29, 38, and >52 wk were observed in three
retreated mice. The duration of remission in the other retreated mice
was 12.6 ± 3.9 wk. Survival curves are shown in Fig. 2.
Anti-DNA Abs
IgG anti-dsDNA Abs and anti-dsDNA Abs of the IgG2a isotype were measured biweekly. IgG2a Abs are the predominant isotype deposited in the kidneys of NZB/NZW F1 mice (15). Control mice and mice treated with CTLA4Ig or anti-CD40L as single therapy all developed high-titer IgG2a anti-dsDNA Abs by the age of 28.4 ± 6 wk. Combination-treated mice developed IgG2a anti-dsDNA Abs at 42.6 ± 10.3 wk (p < 0.0001, data not shown). After retreatment, anti-dsDNA Abs did not decrease concurrent with the disappearance of proteinuria (data not shown).
ELISPOT assays
We have previously shown that long-term CTLA4Ig treatment does not
alter either the polyclonal expansion of IgM Abs or the serum levels of
IgG Abs in NZB/NZW F1 mice (8).
Similarly, total serum IgM and IgG levels were unaffected by
combination CTLA4Ig/anti-CD40L treatment (data not shown). B cells of
NZB/NZW F1 mice spontaneously secrete Abs in
vitro. To enumerate total numbers of Ig-secreting and anti-dsDNA
Ab-producing B cells in the treated mice and follow their kinetics,
total Ig and anti-dsDNA ELISPOTs were performed on spleen samples
from combination-treated NZB/NZW F1 mice at
16–20 wk after the first treatment and compared with age-matched
hamster IgG and IgG2a treated controls. The frequency of IgM
anti-DNA-secreting B cells in the spleens of treated mice was
similar to that seen in young NZB/NZW mice and was significantly
different from that observed in age-matched control mice
(p < 0.03). Significant differences were also
observed for IgG Ab-producing cells. Sixteen to 20 wk after the first
treatment, the frequency of IgG anti-dsDNA Ab-secreting B cells was
60-fold less in treated mice than in age-matched controls
(p = 0.0003). This effect was partially
accounted for by a 4-fold reduction in overall numbers of IgG-secreting
cells in the spleens (p < 0.002), but the
majority of the effect appeared to be due to failure of the expansion
of IgG anti-dsDNA Ab-secreting cells that occurs with age in
unmanipulated mice (Fig. 3). Variable
results were observed in mice that had been treated a second time. In
these mice, total numbers of IgM- and IgG-secreting B cells were not
different from controls, but there was a decrease in IgG
anti-DNA-secreting B cells in three of the five mice
(0.1–4/105 cells), including two that
were studied at the earliest time, 4 wk post-treatment (data not
shown).
Analysis of hybridomas
Highly activated B cells from NZB/NZW F1
mice will spontaneously generate hybridomas without the need for
immunization. Spleen cell fusions were performed to determine the
activation state of anti-DNA Ab-producing B cells and to determine
whether they had been anergized. Hybridomas were generated with the
standard NSO fusion partner immediately after splenectomy and following
a 2-day stimulation with LPS that allows generation of hybridomas from
anergic B cells. Far fewer DNA-binding hybridomas of the IgG class were
recovered from combination-treated mice than from controls
(p = 0.0001, Fig. 4). Furthermore, there was no rescue of
autoreactive hybridomas using LPS-stimulated cells (data not shown),
indicating that anergy is not a major mechanism for the observed
results. These data, together with the ELISPOT data, suggest that
the age-related proliferation and activation of IgG anti-dsDNA
Ab-producing B cells had been blocked by short-term combination
treatment. In the mice studied after the second treatment, IgG
anti-DNA-producing hybridomas were recovered, even in mice that had
low numbers of anti-DNA-secreting cells by ELISPOT, but the
frequency was still less than in untreated controls
(p = 0.0003, Fig. 4)
Flow cytometry
Spleen cells from six combination-treated and six age-matched
nephritic control mice (34–38 wk) were analyzed by FACS for expression
of B and T cell markers. Three 22-wk-old NZB/NZW
F1 mice and two BALB/c mice were examined as
negative controls. The total number of spleen cells was increased in
the control mice compared with either the young or the treated mice
(1.33 ± 0.54 x 108 in controls vs
0.7 ± 0.25 x 108 in treated mice;
p < 0.02, and 0.9 ± 0.1 x
108 in young mice). Untreated NZB/NZW
F1 mice had the same proportions of B and T cells
as normal BALB/c controls. Treated mice had decreased numbers of B
cells (p < 0.003, Fig. 5). Young NZB/NZW
F1 mice had normal numbers of CD8 cells; however,
older nephritic mice displayed a loss of CD8 cells with a markedly
increased CD4:CD8 ratio. In contrast, the treated mice had normal
numbers of CD8+ cells and a normal CD4:CD8 ratio
(p < 0.02 vs age-matched controls). Young
NZB/NZW F1 mice showed evidence of CD4 T cell
activation as demonstrated by increased expression of the early
activation marker CD69. Even higher numbers of activated CD4 cells were
observed in the older NZB/NZW F1 mice. In treated
mice, levels of CD69 expression were comparable with the BALB/c
controls (p < 0.0001 vs untreated
controls, Fig. 5, left panel). Young NZB/NZW
F1 mice had similar numbers of naive
(CD44lowCD62Lhigh) and
memory (CD44highCD62Llow)
CD4 cells as BALB/c mice. However, in older nephritic mice >80% of
the CD4 T cells had a memory phenotype and <5% of the cells had a
naive phenotype. This phenotypic pattern was also observed in
Ad-CTLA4Ig-treated mice (Fig. 5, right panel). However, in
combination-treated mice transition of CD4 T cells from the naive to
the memory compartment was inhibited (p <
0.003 vs untreated controls).
We also examined three mice that were treated a second time after the development of nephritis and entered sustained remission. The B and T cell phenotype of these mice was no different from that of untreated sick controls (data not shown).
Class switching
To determine whether the effects on IgG anti-dsDNA
Ab-producing B cells was due to a block in class switching,
semiquantitative RT-PCR was performed on spleen mRNA for sterile
I2b-C2b class switch transcripts.
Sixteen to 20 wk after treatment there was a decrease in the class
switch transcripts in the treated mice compared with controls (Fig. 6). A similar decrease in class switch
transcripts was observed in three of four spleens harvested 4–8 wk
after second treatment of mice that had developed proteinuria (Fig. 6).
Similar results were observed for IgG1 class switch transcripts (data
not shown).
|
The VHBW-16 gene, a member of the J558 gene family, has been shown to be strongly associated with pathogenic anti-dsDNA Abs both in NZB/NZW F1 and MRL/lpr mice (16). Despite its presence in the germline, VHBW-16 is not expressed in several normal mouse strains, even by naive cells, unless such mice are experimentally induced to mount an anti-dsDNA Ab response by immunization with DNA complexed to a DNA-binding protein. In these cases, the autoantibodies either are all of the IgM isotype or are of low affinity (17). These findings indicate that Abs using this gene are regulated in the peripheral B cell compartment of normal mice. High-affinity anti-dsDNA Ab activity in NZB/NZW F1 mice is further associated with class switching from IgM to IgG and with the presence of basic amino acids, particularly arginine, in CDR2 (acquired by somatic mutation) and CDR3 (acquired during gene rearrangement in the bone marrow) of VHBW-16 (8, 17). We have previously shown that somatic mutations accumulate in this gene with age (8). The VHBW-16 gene is thus an excellent marker to examine the effect of costimulatory blockade both on the selection of naive autoreactive B cells and on activated B cells undergoing somatic mutation.
Analysis of the VHBW-16 sequences from
combination-treated mice revealed several interesting findings. First,
there was no difference in the number of sequences containing arginines
in the CDR3 compared with age-matched controls, indicating that
regulation of naive bone marrow emigrants did not appear to be affected
by therapy (data not shown). Second, the frequency of somatic mutation
was decreased in the treated mice compared with untreated controls. The
number of sequences containing no mutations or one mutation in treated
mice was no different from the number of sequences in young NZB/NZW
mice but was significantly different from age-matched controls
(p < 0.004, Fig. 7). Together these data point to a
long-term effect of treatment on the ability of B cells using this gene
to receive or respond to T cell help (Table I). Third, there were
striking differences in the nature of the mutations that accumulated in
the treated mice. Most mutations in the CDRs were found in CDR2, which
has four contiguous RGYW hot spots spanning positions 55–58. All four
of these positions were mutated in control mice; however, in treated
mice far fewer mutations were observed at positions 55–57. A
frequently observed change in positions 55, 56, and 58 in untreated
mice was mutation to arginine, a positively charged amino acid that
confers increased affinity for DNA. In contrast mutation to arginine
was infrequent in the treated mice, the most frequently observed change
in combination-treated mice being to threonine, a neutral amino acid
(Fig. 8).
|
To determine whether the suppression of the IgG anti-DNA Ab
response was due to a global effect on B cell responses or was specific
to the autoreactive B cell response, we immunized mice 8–10 wk after
treatment with the hapten oxazolone without adjuvant. Control mice
mounted a strong IgG anti-oxazolone response. In contrast, mice
that had been injected with adenovirus-expressing CTLA4Ig and that were
expressing high levels of CTLA4Ig in the serum were unable to respond
to oxazolone, indicating an inability to mount an immune response to a
T-dependent Ag. Mice treated with either 2 wk of single CTLA4Ig or
anti-CD40L therapy or with the short-term combination mounted an
anti-oxazolone response equivalent to controls at both serum
dilutions tested, indicating that once the CTLA4Ig and anti-CD40L
had cleared from the serum the immune response to foreign Ag was not
compromised (Fig. 9). To determine the
effect of treatment on expansion of Ag-specific B cells, ELISPOT assays
were performed on control and combination-treated mice. The frequency
of IgG anti-oxazolone-secreting cells was not significantly
different between treated mice and untreated controls, but the
frequency of IgG anti-DNA-secreting cells was significantly
diminished (Fig. 10, p
< 0.03). Hybridomas were generated from the spleens and tested for
binding to oxazolone and to DNA. The frequency of IgG oxazolone-binding
hybridomas was similar in treated and control mice (1.2 vs 1.3%),
indicating that there was no effect of treatment on activation of
anti-oxazolone-secreting B cells. However, the frequency of IgG
anti-DNA hybridomas was diminished 10-fold in the treated mice (0.2
vs 2.0%, p = 0.003). In control mice 36% of the
anti-oxazolone hybridomas were cross-reactive with DNA compared
with 6% in the treated mice (p = 0.03).
To further determine whether affinity maturation proceeded normally in
the combination-treated mice, IgG cDNA libraries for the
VH-Ox15 gene were generated from the spleens of
four treated and four control mice by RT-PCR. We have previously shown
that 30–40% of anti-oxazolone hybridomas in untreated NZB/NZW
mice use this H chain gene (M. Mihara and A. Davidson, unpublished
observation). Very little PCR product was recovered from cDNA of three
unimmunized mice and insufficient numbers of clones were recovered for
analysis (data not shown). More than 20 sequences from each immunized
group were analyzed for mutation frequency. Analysis of the
VH-oxazolone sequences revealed evidence for
affinity maturation in both treated and control mice with high
replacement:silent ratios in the CDRs (Table I). These studies in sum
show that treated mice are able to mount a mature IgG response to
foreign Ag with concomitant regulation of cross-reactive autoreactive B
cells.
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
We have previously shown that long-term therapy with CTLA4Ig has no effect on early polyclonal activation of B cells but that it prevents the later steps of T cell-dependent B cell activation that precedes nephritis onset. However, CTLA4Ig does not prevent accumulation of T cells with a memory phenotype, and disease onset occurs within 4–8 wk of cessation of treatment (8). Furthermore, continuous high-dose CTLA4Ig therapy is immunosuppressive, resulting in complete suppression of humoral immune responses to both alloantigen (23) and oxazolone.
In this study we show that short-term combination therapy resulted in a long delay in onset of disease with suppression of autoreactive B cells that was not due to global long-term immunosuppression. This long-term response to treatment was found to be due to modulation of both T and B cell function. Untreated NZB/NZW F1 mice have excessive T cell activation as evidenced by increased expression of the activation marker CD69 on CD4 cells, a progressive increase in CD4 T cells in the spleen, and accumulation of CD4 T cells bearing the memory phenotype (CD44+CD62L-) (8). The emergence of all of these abnormalities was substantially delayed by 2 wk of treatment with combination costimulatory blockade. However, because T cells can be activated by autoreactive B cells it is not clear whether this was due to a primary effect on T cells or whether the absence of excessive T cell activation was due to absence of autoreactive B cells (24).
There was a clear decrease in the proportion and absolute numbers of B cells in the spleens of treated mice, which was evident even 16–20 wk after treatment. This effect was not observed using long-term administration of either CTLA4Ig (8) or anti-CD40L (X. Wang, W. Huang, M. Mihara, J. Sinha, and A. Davidson, manuscript in preparation) as single agents. CD40L expression on T cells is up-regulated early in the course of murine SLE and may rescue B cells from apoptosis during early B cell activation. B cell expression of B7.2, which occurs early after BCR stimulation, may also rescue B cells from apoptosis by facilitating the T cell release of antiapoptotic cytokines such as IL-4 (25, 26). Therefore, CTLA4Ig and anti-CD40L may act synergistically to block antiapoptotic signals and facilitate apoptosis of B cells during early B cell activation. Despite the decrease in B cell numbers, combination therapy did not appear to have major functional effects on naive autoreactive B cells. However, treatment did clearly prevent proliferation of IgM anti-DNA Ab-producing B cells as well as their activation and class switching to IgG.
Regulation of IgG anti-DNA Abs appeared to occur by several mechanisms. Flow cytometry analysis revealed a decrease in generalized T cell activation as described above. Precursors of autoreactive B cells reside in the marginal zone and B1 B cell compartments (27, 28) and have few somatic mutations. The large number of unmutated VHBW-16 genes found in the cDNA libraries from treated mice could be accounted for by prevention of trafficking of autoreactive precursors to the germinal centers. Therefore, it is of interest that the number of spontaneous germinal centers in the spleen was markedly diminished in the treated mice compared with controls, as observed by immunohistochemistry (data not shown). Alternatively, this effect could be the result of a general decrease in the number of cell divisions secondary to decreased T cell help (29).
Even when somatic mutation occurred, there appeared to be an alteration of selection of B cells producing mutated Abs. It is known that B cells that acquire specificity for both an eliciting foreign Ag and self-Ag through somatic mutation arise frequently in normal mice but are usually eliminated by apoptosis and do not enter the memory compartment (30, 31). In NZB/NZW F1 mice peripheral regulation of autoreactive B cells is altered and they enter both the memory and long-lived plasma cell compartments (31, 32). Examination of the immune response to oxazolone showed that in control-aged NZB/NZW F1 mice many oxazolone/dsDNA double-reactive Abs were elicited by oxazolone immunization and could be rescued as hybridomas without LPS stimulation. In contrast, Ag-selected class-switched Abs to oxazolone could be effectively generated in the combination-treated mice with concomitant regulation of the IgG anti-DNA Ab response. Thus, combination costimulatory blockade appears to allow the mice to maintain this normal aspect of peripheral B cell self-tolerance.
An effect upon B cell selection could also be seen upon analysis of the mutated VHBW-16 genes in the IgG cDNA libraries of the treated mice. This gene is strongly associated with anti-dsDNA Ab activity and with glomerular binding activity in NZB/NZW F1 mice (16), but its expression is regulated in the peripheral B cell compartment of normal mice (17). It has been previously reported that selection against genes with CDR3 bearing arginine, a basic amino acid with affinity for positively charged DNA, is a major mechanism of regulation of the VHBW-16 gene in normal mice that have experimentally been induced to mount an anti-dsDNA Ab response. This selection occurs mainly in the naive B cell repertoire, as these differences could be seen even in unmutated IgM Abs (17). In contrast, the NZB/NZW F1 mice treated with combination costimulatory blockade had no differences in arginine usage in CDR3, suggesting that treatment had no effect on selection of the naive B cell repertoire. The main differences between treated and control groups were observed in the CDR2, where an accumulation of arginine residues was observed in control but not in treated mice. A similar absence of arginine mutations was observed in Ad-CTLA4Ig treated mice (8). Although it has not been formally shown for this gene that arginine mutations in CDR2 are associated with high-affinity DNA binding, these data are suggestive that selection against mutations to arginine occurred in the treated mice. Similar findings have been reported in bcl-2 transgenic mice immunized with the hapten p-azophenylarsonate in which dual anti-arsonate/anti-DNA hybridomas contained a much higher percentage of mutations to arginine than did anti-arsonate hybridomas from wild-type mice (31).
Because onset of proteinuria occurred earlier than expected (11), we administered a second 2-wk course of combination therapy at the time of onset of fixed proteinuria (>300 mg/dl). This treatment effectively induced remission of nephritis in >50% of previously treated mice (defined as proteinuria <30 mg/dl lasting >6 wk after treatment initiation) compared with 17% of previously untreated controls. The mechanism for this remission is not completely clear. Despite the disappearance of proteinuria within 2–3 wk, there was no immediate decrease in circulating anti-dsDNA Abs, nor was there a reversal of the activated T cell phenotype. Although there was a decrease in DNA-binding B cells as evidenced by a decrease in ELISPOTs and hybridomas compared with controls, we could not tell from our experiments whether this preceded or followed the second round of therapy. However, in three mice IgG anti-DNA Ab-producing B cells were virtually absent from the spleen 4–5 wk after therapy. In these mice, serum anti-DNA Abs did not decrease over this period, suggesting that the serum Abs were arising from B cells outside the spleen, most likely from long-lived plasma cells that do not require T cell help to survive (33). Class switching was affected, but examination of VHBW-16 libraries revealed a similar profile of sequences to that observed in control mice (data not shown). It is possible that the rapid response to a second course of treatment may have resulted from an alteration of other inflammatory cells or of effector functions in the target organs. We have recently shown similar results in a disease remission induction protocol in previously untreated mice in which a single dose of cyclophosphamide was added to the 2-wk combination therapy regimen. In these mice, renal remission was induced despite the continued presence of Ig and complementdeposition in the kidneys (34) (J. Sinha, L. Schiffer, X. Wang,W. Huang, A. Akkerman, K. Hiromatsu, and A. Davidson,manuscript in preparation). In sum, these results suggest that costimulatory blockade suppresses autoantibody formation and the initiation of disease when used in prevention studies but can also significantly suppress the effector response to immune complex deposition when used in remission induction studies. Understanding the effects of costimulatory blocking regimens in the various phases of autoimmune disease is essential to optimization of such treatments for use in humans with already established disease.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Current address: Chugai Pharmaceuticals, Gotemba-shi, Shizuoka, Japan.
3 Address correspondence and reprint requests to Dr. Anne Davidson, Departments of Medicine and Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, U505, Bronx, NY 10461. E-mail address: davidson{at}aecom.yu.edu
4 Abbreviations used in this paper: SLE, systemic lupus erythematosus; CD40L, CD40 ligand; CDR, complementarity-determining region.
Received for publication October 18, 2001. Accepted for publication December 13, 2001.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  M. M. P. C. Donners, L. Beckers, D. Lievens, I. Munnix, J. Heemskerk, B. J. Janssen, E. Wijnands, J. Cleutjens, A. Zernecke, C. Weber, et al. The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling Blood, May 1, 2008; 111(9): 4596 - 4604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ahuja, J. Shupe, R. Dunn, M. Kashgarian, M. R. Kehry, and M. J. Shlomchik Depletion of B Cells in Murine Lupus: Efficacy and Resistance J. Immunol., September 1, 2007; 179(5): 3351 - 3361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Choudhury, M. A. Maldonado, P. L. Cohen, and R. A. Eisenberg The Role of Host CD4 T Cells in the Pathogenesis of the Chronic Graft-versus-Host Model of Systemic Lupus Erythematosus J. Immunol., June 15, 2005; 174(12): 7600 - 7609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ramanujam, X. Wang, W. Huang, L. Schiffer, C. Grimaldi, A. Akkerman, B. Diamond, M. P. Madaio, and A. Davidson Mechanism of Action of Transmembrane Activator and Calcium Modulator Ligand Interactor-Ig in Murine Systemic Lupus Erythematosus J. Immunol., September 1, 2004; 173(5): 3524 - 3534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Daoussis, A. P. Andonopoulos, and S.-N. C. Liossis Targeting CD40L: a Promising Therapeutic Approach Clin. Vaccine Immunol., July 1, 2004; 11(4): 635 - 641. [Full Text]
|
|
|
|
 |
|
 N. Ardjomand, J. C. McAlister, N. J. Rogers, P. H. Tan, A. J. T. George, and D. F. P. Larkin Modulation of Costimulation by CD28 and CD154 Alters the Kinetics and Cellular Characteristics of Corneal Allograft Rejection Invest. Ophthalmol. Vis. Sci., September 1, 2003; 44(9): 3899 - 3905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Schiffer, J. Sinha, X. Wang, W. Huang, G. von Gonsdorff, M. Schiffer, M. P. Madaio, and A. Davidson Short Term Administration of Costimulatory Blockade and Cyclophosphamide Induces Remission of Systemic Lupus Erythematosus Nephritis in NZB/W F1 Mice by a Mechanism Downstream of Renal Immune Complex Deposition J. Immunol., July 1, 2003; 171(1): 489 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L E Schiffer, N Hussain, X Wang, W Huang, J Sinha, M Ramanujam, and A Davidson Lowering anti-dsDNA antibodies--what's new? Lupus, December 1, 2002; 11(12): 885 - 894. [Abstract] [PDF]
|
|
|
|
 |
|
 G.-C. Fan and R. R. Singh Vaccination with Minigenes Encoding VH-derived Major Histocompatibility Complex Class I-binding Epitopes Activates Cytotoxic T Cells that Ablate Autoantibody-producing B Cells and Inhibit Lupus J. Exp. Med., September 16, 2002; 196(6): 731 - 741. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||
